Assistant Professor, Medicine, University of Colorado School of Medicine
Oncology
Dr. Robert C. Doebele, MD
|
|
Give Review
Robert C. Doebele practices Oncology. He went to Perelman School of Medicine at the University of Pennsylvania. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Robert C. Doebele, MD is a published doctor and has 46 publications published. The lastest was: 'Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization.' Robert Doebele accepts Medicare.
Publications
- Molecularly targeted therapies in non-small-cell lung Cancer annual update 2014.
- Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer.
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy.
- Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonSquamous, advanced/metasta...
- Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.
- The Minority Report: Targeting the Rare Oncogenes in NSCLC.
- A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Can...
- EGFR Exon 19 Deletion Mutations and Systemic/Central Nervous System Miliary Metastasis: Clinical Correlations and Response to Therapy.
- A Nice Problem to Have: When ALK Inhibitor Therapy Works Better Than Expected.
- Targeted therapies in non-small cell lung Cancer: emerging oncogene targets following the success of epidermal growth factor receptor.
- Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lun...
- The evolution of tumor classification: a role for genomics?
- ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intra-tumoral Heterogeneity for Molecular Drivers.
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung Cancer.
- Native and rearranged ALK copy number and rearranged cell count in non-small cell lung Cancer: Implications for ALK inhibitor therapy.
- Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR.
- Molecular Pathways: ROS1 Fusion Proteins in Cancer.
- Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kin...
- Targeted therapies: Time to shift the burden of proof for oncogene-positive Cancer?
- Re-examination of Maintenance Therapy in Non-Small Cell Lung Cancer with the Advent of New Anti-Cancer Agents.
- Symptomatic reduction in free testosterone levels secondary to crizotinib use in male Cancer patients.
- Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.
- Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid Malignancies, with an ...
- Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung Cancer.
- Treating ALK-positive lung Cancer--early successes and future challenges.
- Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer.
- Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer.
- Novel Fc gamma receptor I family gene products in human mononuclear Cells.
- A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced ...
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung Cancer harbouring ALK gene rearrangement: a retrospective analysis.
- Genetic testing for lung Cancer: reflex versus clinical selection.
- Anaplastic lymphoma kinase gene rearrangements in non-small cell lung Cancer are associated with prolonged progression-free survival on pemetrexed.
- Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC Cell lines through de-repression of FGFR2 and FGFR3 expression.
- Optimizing the detection of lung Cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.
- Biomarkers are here to stay for clinical research and standard care.
- New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung Cancer.
- A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extraCellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to contr...
- Anthrax edema toxin inhibits endothelial Cell chemotaxis via Epac and Rap1.
- Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides.
- Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymor...
- Determination of the HLA-DM interaction site on HLA-DR molecules.
- Accessory molecules for MHC class II peptide loading.
- Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization.
- Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
- PrlA and PrlG suppressors reduce the requirement for signal sequence recognition.
Schools
University Of Pennsylvania School Of Medicine
University Of Chicago Program
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Chicago -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
University of Colorado Hospital
Drug Facts
| NPI NUMBER | 1952424830 | |
| NPPES Provider LastName | DOEBELE | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 800452545 | |
| NPPES Provider State | CO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 158.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952424830 |
| Last Name Of The Provider | DOEBELE |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
Dr. Han Myint, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Eamon M. Berge, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jonathan A. Gutman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael Gordon, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Colin D. Weekes, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Vibha T. Thomas, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Virginia Borges, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karl D. Lewis, MD
This Doctor is OpenDoctor Recommended.
|